What the research found

When skin is exposed to UVB radiation, the immune system responds by sending neutrophils to the damaged area. These immune cells then trigger a self-destructive process that releases their internal contents—proteins and DNA—creating structures called neutrophil extracellular traps (NETs). While NETs normally help fight pathogens, in this sterile inflammatory context they appear to amplify skin damage rather than protect it.

Researchers examined skin samples from people with sun-damage conditions and confirmed elevated NET levels compared to healthy controls. In mice exposed to UVB, blocking a key enzyme (PAD4) required for NET formation using a compound called GSK484 significantly reduced visible skin damage, inflammation markers, oxidative stress, and cell death. The protective effect was substantial but incomplete—GSK484 treatment didn't eliminate UVB damage entirely, only reduced its severity. Genetic silencing of a receptor called CCDC25 in skin cells produced similar benefits, suggesting this could be another intervention point.

Why it matters for you

If you're tracking inflammatory biomarkers (IL-6, TNF-α, C-reactive protein), sun exposure may be worsening your numbers through a pathway that extends beyond direct DNA damage. Your immune response itself—specifically NET formation—appears to drive additional inflammation and cell death in skin tissue. This implies that anti-inflammatory protocols might offer modest benefit beyond sunscreen, though prevention remains primary.

The involvement of the JNK pathway (part of the MAPK cascade) is worth noting if you're already monitoring or trying to influence inflammatory signaling. Compounds that inhibit PAD4 or block CCDC25 don't currently exist as supplements or readily accessible treatments, but understanding this mechanism may inform future development of topical or systemic anti-inflammatories specifically for sun-exposed skin.

For practical purposes: sunscreen and sun avoidance remain your best tools. This work suggests that if you do get significant UVB exposure, your subsequent inflammatory flare may be partly driven by NET-mediated damage rather than radiation alone—a distinction that might eventually enable targeted dampening of that secondary response.

Caveats

  • Mouse model: Benefits shown in mice may not translate directly to human skin; the dosing and kinetics differ substantially
  • PAD4 inhibitor not clinically available: GSK484 is a research compound; no equivalent over-the-counter treatment exists
  • AAV gene therapy is experimental: CCDC25 blockade was achieved via viral vector in mice—not a realistic near-term intervention for humans
  • Incomplete protection: GSK484 reduced but did not prevent UVB damage, limiting its potential as a standalone strategy
  • Early mechanistic work: This establishes a pathway but doesn't yet support clinical recommendations